GNFT Stock Overview
A late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Genfit S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.03 |
| 52 Week High | €5.86 |
| 52 Week Low | €2.90 |
| Beta | 1.12 |
| 11 Month Change | -25.32% |
| 3 Month Change | 3.47% |
| 1 Year Change | 31.32% |
| 33 Year Change | 31.97% |
| 5 Year Change | -72.24% |
| Change since IPO | -68.94% |
Recent News & Updates
Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%
Nov 16
We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit
Sep 27Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%
Sep 26Recent updates
Genfit S.A. (EPA:GNFT) Not Doing Enough For Some Investors As Its Shares Slump 25%
Nov 16We Think Shareholders Should Be Aware Of Some Factors Beyond Genfit's (EPA:GNFT) Profit
Sep 27Genfit S.A. (EPA:GNFT) Held Back By Insufficient Growth Even After Shares Climb 26%
Sep 26Growth Investors: Industry Analysts Just Upgraded Their Genfit S.A. (EPA:GNFT) Revenue Forecasts By 28%
Sep 24Genfit (EPA:GNFT) Seems To Use Debt Quite Sensibly
Sep 22Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%
May 23Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues
Jan 03Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?
Sep 22Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)
Jul 05Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected
Jun 23We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease
Dec 28New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)
Sep 30Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term
Jun 29Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.
Mar 14Is Genfit (EPA:GNFT) A Risky Investment?
Nov 28
Shareholder Returns
| GNFT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -17.6% | -7.7% | -0.3% |
| 1Y | 31.3% | -26.4% | -3.5% |
Return vs Industry: GNFT exceeded the French Biotechs industry which returned -26.5% over the past year.
Return vs Market: GNFT exceeded the French Market which returned -2.5% over the past year.
Price Volatility
| GNFT volatility | |
|---|---|
| GNFT Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: GNFT's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: GNFT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 169 | M. Prigent | www.genfit.com |
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Genfit S.A. Fundamentals Summary
| GNFT fundamental statistics | |
|---|---|
| Market cap | €200.69m |
| Earnings (TTM) | €22.27m |
| Revenue (TTM) | €80.47m |
9.0x
P/E Ratio2.5x
P/S RatioIs GNFT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNFT income statement (TTM) | |
|---|---|
| Revenue | €80.47m |
| Cost of Revenue | €0 |
| Gross Profit | €80.47m |
| Other Expenses | €58.20m |
| Earnings | €22.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 100.00% |
| Net Profit Margin | 27.67% |
| Debt/Equity Ratio | 63.9% |
How did GNFT perform over the long term?
See historical performance and comparison